z-logo
open-access-imgOpen Access
Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study
Author(s) -
D.H. Pafundi,
Nadia N. Laack,
Ryan S. Youland,
Ian F. Parney,
Val J. Lowe,
Caterina Giannini,
Brad Kemp,
Michael P. Grams,
James M. Morris,
Jason M. Hoover,
Leland Hu,
Jann N. Sarkaria,
Debra H. Brinkmann
Publication year - 2013
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/not002
Subject(s) - histopathology , medicine , biopsy , glioma , nuclear medicine , radiation therapy , stereotactic biopsy , radiology , biodistribution , pathology , in vivo , microbiology and biotechnology , cancer research , biology
Delineation of glioma extent for surgical or radiotherapy planning is routinely based on MRI. There is increasing awareness that contrast enhancement on T1-weighted images (T1-CE) may not reflect the entire extent of disease. The amino acid tracer (18)F-DOPA (3,4-dihydroxy-6-[18F] fluoro-l-phenylalanine) has a high tumor-to-background signal and high sensitivity for glioma imaging. This study compares (18)F-DOPA PET against conventional MRI for neurosurgical biopsy targeting, resection planning, and radiotherapy target volume delineation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom